Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 2, 2000, Pages 143-150

  Atarashi, Hirotsugu ^a   Kuruma, Akinori ^a   Yashima, Masa Aki ^a   Saitoh, Hirokazu ^a   Ino, Takeshi ^a   Endoh, Yasumi ^a   Hayakawa, Hirokazu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LANDIOLOL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; MALE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; TACHYCARDIA, SUPRAVENTRICULAR; TACHYCARDIA, VENTRICULAR; UREA; VENTRICULAR PREMATURE COMPLEXES;

EID: 0033841803     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.108733     Document Type: Article

References (15)

1. Development of highly cardioselective ultra short-acting β-blocker, ONO-1101
2. 1-blocking agent in healthy volunteers
3. 1-blocker, on experimentally induced canine tachycardia and arrhythmia
4. Functional, angiographic and intracoronary doppler flow characteristics in symptomatic patients with myocardial bridging: Effect of short-term intravenous beta-blocker medication
5. Esmolol aids extubation in intensive care patient with ischaemic pulmonary oedema
6. Esmolol: A titratable short-acting intravenous beta blocker for acute critical care setting
7. Esmolol: A new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias
8. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite
9. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle
10. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: Results of a multicenter, baseline-controlled safety and efficacy study in 160 patients
11. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias
12. Safety and efficacy of esmolol (ASL-8052: An ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias
13. A double-blind trial of metoprolol in acute myocardial infarction: Effects on ventricular tachyarrhythmias
14. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia
15. Sotalol: A new β-adrenergic blocker for ventricular arrhythmias